Charles Brenton Huggins redirected the trajectory of oncology by establishing that hormonal shifts could effectively suppress malignant tumor growth. Working at the University of Chicago, he demonstrated that prostate and breast cancers, once considered untreatable in their advanced stages, were often dependent on sex hormones to proliferate, leading to the development of early systemic endocrine therapies.
Academic Formation
Born in Halifax in 1901, Huggins completed his undergraduate studies at Acadia University by age 19. He proceeded to Harvard Medical School, earning his MD in 1924. His early surgical training took place at the University of Michigan, where he completed an internship and residency under the supervision of Frederick A. Coller. This period provided the technical foundation that would later support his transition from general surgery to specialized physiological research.
Twenty questions, eight minutes on the clock, and a percentile measured against everyone who has taken it. No sign-up.
Take the IQ test →University of Chicago Tenure
In 1927, Dallas Phemister recruited Huggins to the faculty of the newly formed University of Chicago Medical School. As one of the institution's eight original staff members, he was assigned to the urology department. To build his expertise, he undertook a research sabbatical in 1931 at the Lister Institute in London, working in the laboratory of Robert Robison. He advanced through the ranks, securing a full professorship by 1936 and eventually leading the Ben May Laboratory for Cancer Research from 1951 until 1969.
Hormonal Interventions in Oncology
Huggins moved from studying bone physiology to investigating the male urogenital tract. In 1939, he developed a technique to isolate prostate fluid from dogs, which allowed him to observe how androgen levels influenced prostate activity. By 1941, he published findings demonstrating that surgical castration or estrogen administration could shrink metastatic prostate tumors. He later expanded this conceptual framework to breast cancer, creating the 7,12-dimethylbenz(a)anthracene rat model to facilitate further experimental study of tumor behavior.
Innovation in Biochemistry
To quantify the effectiveness of his interventions, Huggins pioneered the use of colorimetric methods. He coined the term 'chromogenic substrates' to describe the substances he developed to detect and measure enzymes such as phosphatases, glucuronidases, and esterases within blood samples. These diagnostic tools allowed for precise monitoring of hormonal impact on malignant tissues, cementing his dual identity as a surgeon and a rigorous experimental physiologist.
Fast facts
- Born: 1901, Halifax
- Died: 1997, Chicago
- Education: Acadia University, Harvard Medical School
- Nobel Prize in Physiology or Medicine: 1966
- Lasker-DeBakey Clinical Medical Research Award: 1963
- Citizenship: Canada, United States
- Professional motto: Discovery is our business
Questions readers ask
What was the core discovery for which Huggins received the Nobel Prize?
He discovered that prostate cancer growth is hormone-dependent and can be suppressed by eliminating androgens or administering estrogens.
Did Huggins continue his research throughout his career?
Yes, he maintained a commitment to laboratory work for his entire professional life, continuing to perform experiments in his 90s.
Achievements
- Nobel Prize in Physiology or Medicine — 1966
- Lasker-DeBakey Clinical Medical Research Award — 1963
- Affiliated with University of Chicago and University of Michigan
- Educated at Harvard Medical School and Acadia University
- Worked as physiologist, oncologist and university teacher
